Responses
Regular and Young Investigator Award Abstracts
Biomarkers, Immune Monitoring and Novel Technologies
192 Clinicopathologic, genomic and immunophenotypic features and outcomes to immune checkpoint inhibitors in patients with mucinous lung adenocarcinoma
Compose a Response to This Article
Other responses
No responses have been published for this article.
